SYSTAAQ Diagnostic Products Receives CE Mark for Molecular Diagnostics
SYSTAAQ Diagnostic Products (https://www.systaaq.com/) has announced today that it has received CE Mark for its HBV and HCV molecular diagnostic tests for the detection and quantitation of Hepatitis B and Hepatitis C viruses respectively. By achieving certification for these test, the Prince William Science Accelerator tenant, a Virginia-based firm, can sell these tests for clinical use across Europe and other geographies that recognize the designation.
SYSTAAQ Diagnostic Products is one of the leaders in molecular diagnostics, offering a wide range of products and services in the field of molecular testing. SYSTAAQ has developed highly sensitive and specific molecular diagnostic test for a number of infectious diseases. SYSTAAQ’s HBV and HCV Real Time PCR kits are molecular tests for detection and quantitation of Hepatitis B and Hepatitis viral loads by means of Real Time PCR.
Danial Richardson, Chairman Scientific Advisory Board at SYSTAAQ said that with high sensitivity and specificity of the tests, these tests can play a transformative role in the way healthcare providers diagnose the infections at a very early stage”. The tests will soon be launched in Europe, Asia and South America.
Latest posts by Chris Frew (see all)
- Serial Entrepreneurs of the Biohealth Capital Region - September 17, 2019
- New Pediatric Rare Disease Company, Abri Science, Launches in Baltimore to address Phenylketonuria (PKU) - September 17, 2019
- Immunomic Therapeutics Appoints Harvard’s Brain Tumor Expert, Dr. E. Antonio Chiocca, to its Scientific Advisory Board - September 17, 2019